ONC
BeOne Medicines AG · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +12.5% ·
share flow +8.0% ·
net new positions +11.1%
· formula
Broad accumulation: rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 93 | -6 | 22.51M | $6.43B | +4 | −10 |
| Q1 2026 | 100 | +2 | 21.59M | $6.42B | +8 | −6 |
| Q4 2025 | 97 | +2 | 20.58M | $6.25B | +2 | n/a |
| Q3 2025 | 14 | -1 | 11.95M | $4.07B | +1 | −2 |
| Q2 2025 | 12 | -4 | 11.51M | $2.79B | +1 | −5 |
| Q1 2025 | 14 | +4 | 13.65M | $3.71B | +4 | n/a |
| Q4 2024 | 10 | +1 | 12.37M | $2.28B | +1 | n/a |
| Q3 2024 | 9 | +1 | 12.34M | $2.77B | +1 | n/a |
| Q2 2024 | 8 | n/a | 11.43M | $1.63B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | PRIMECAP Management ✦ | 4.97M | -0.2% | $1.12B | 0.8% | ▼ Trim | 2 | SEC ↗ |
| 2 | Baillie Gifford ✦ | 3.71M | +0.7% | $831.98M | 0.6% | ▲ Add | 2 | SEC ↗ ×4 |
| 3 | T. Rowe Price ✦ | 2.70M | +18.8% | $606.20M | 0.1% | ▲ Add | 2 | SEC ↗ ×2 |
| 4 | Point72 Asset Management ✦ | 667.17K | +74.9% | $149.79M | 0.5% | ▲ Add | 2 | SEC ↗ |
| 5 | Norges Bank ✦ (passive) | 106.36K | New | $23.88M | 0.0% | New | 1 | SEC ↗ |
| 6 | Millennium Management ✦ | 57.12K | +314.5% | $12.83M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 7 | Citadel Advisors ✦ | 47.03K | +713.7% | $10.56M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 8 | Marshall Wace ✦ | 45.94K | -11.6% | $10.31M | 0.0% | ▼ Trim | 2 | SEC ↗ ×2 |
| 9 | Geode Capital Management ✦ (passive) | 37.76K | -0.1% | $8.48M | 0.0% | ▼ Trim | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Norges Bank | $23.88M | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 278 holders, 34.74M shares, $10.13B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 5.68K sh · $2.00M
Director · 7.17K sh · $2.51M
Director · 10.36K sh · $3.63M
Director · 1.26K sh · $445,078
Director · 6.56K sh · $2.31M
Officer · 1.11K sh · $418,125
Director · 2.24K sh · $809,120
Director · 40 sh · $14,366
Director · 120 sh · $43,045
Director · 160 sh · $57,115
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology
7.8% of class · View original SEC filing ↗
8.0% of class · View original SEC filing ↗